Sarcoidosis, Pulmonary
27
5
7
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.7%
1 terminated out of 27 trials
92.9%
+6.4% vs benchmark
19%
5 trials in Phase 3/4
31%
4 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (27)
Feasibility of Semaglutide in Advanced Lung Disease
Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy
the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis
Diagnostic Value of EBUS-Guided Transbronchial Mediastinal Cryobiopsy Versus Conventional Bronchoscopic Approaches for Stage I/II Sarcoidosis
Risk Indicators of Sarcoidosis Evolution-Unified Protocol
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
Effectiveness of Methotrexate Versus Prednisone as First-line Therapy for Pulmonary Sarcoidosis
Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis
RCT of Nintedanib in Fibrotic Sarcoidosis
Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease
Peripheral Airway Biopsy in Sarcoidosis
Endobronchial Ultrasound Strain Elastography in Sarcoidosis
SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis
An RCT of NBI vs. White Light Guided Endobronchial Biopsy in Suspected Sarcoidosis
Acthar Gel in Participants With Pulmonary Sarcoidosis
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease